SYNTHON BV
- Country
- 🇪🇸Spain
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.synthon.com
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of GTR in Comparison to Copaxone®
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Synthon BV
- Target Recruit Count
- 794
- Registration Number
- NCT01489254
- Locations
- 🇺🇸
Synthon investigational site 112, Irvine, California, United States
🇺🇸Synthon investigational site 120, Port Charlotte, Florida, United States
🇺🇸Synthon investigational site 130, Sunrise, Florida, United States
News
Zydus and Synthon Partner to Launch Generic Multiple Sclerosis Drug in $637 Million US Market
Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV to commercialize generic Ozanimod capsules for multiple sclerosis treatment in the US market.
Zydus Lifesciences Partners with Synthon for Novel Cancer Drug Development in $1.5 Billion US Market
Zydus Lifesciences has signed an exclusive agreement with Netherlands-based Synthon BV for the development and commercialization of a novel 505(B)(2) oncology product targeting an undisclosed indication in the US market.